F2G Biotech GmbH
22
1
2
14
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
22.7%
5 terminated/withdrawn out of 22 trials
73.7%
-12.8% vs industry average
5%
1 trials in Phase 3/4
14%
2 of 14 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (22)
Olorofim in Early Coccidioidal Meningitis
Role: collaborator
Olorofim Aspergillus Infection Study
Role: lead
Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options
Role: lead
FungiScope - A Global Emerging Fungal Infection Registry
Role: collaborator
A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Renal Impairment
Role: lead
A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Hepatic Impairment
Role: lead
A Biopharmaceutics Study to Assess the Pharmacokinetics of Single Oral and IV Doses of Olorofim
Role: lead
Drug-drug Interaction (DDI) Study to Assess Effect of Itraconazole and Rifampicin Upon Olorofim
Role: lead
Absorption, Metabolism and Excretion of 14C-olorofim in Man
Role: lead
Radiolabelled IV and Oral Metabolism Study of F901318
Role: lead
Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects
Role: lead
Safety and Pharmacokinetics of Oral F901318 (Fluconazole and Posaconazole) IN Aml Leukaemia
Role: lead
Study on Safety and Pharmacokinetics of Intravenous F901318 for Fungal Prophylaxis in AML Patients
Role: lead
Drug/Drug Interactions With F901318
Role: lead
Pharmacokinetics of IV Formulation
Role: lead
Multiple Ascending Oral Dose Study of F901318 in Healthy Subjects
Role: lead
Study of Potential for Interaction of Fluconazole With F901318
Role: lead
Evaluation of Immediate Release Tablet
Role: lead
Single Ascending Oral Dose Study of F901318
Role: lead
F901318 Multiple Ascending Dose Study
Role: lead